HRTpeptide

Tesofensine

Also known as: NS2330, triple monoamine reuptake inhibitor

Wellness

In plain English

Tesofensine is an experimental weight-loss capsule that acts on brain chemicals (noradrenaline, dopamine, and serotonin) to reduce appetite. In an early trial it produced meaningful weight loss, but it has never completed the large late-stage studies needed for approval, and it is not an FDA-approved medication. Because it stimulates the nervous system, dry mouth, sleep disturbance, faster heart rate, and mood or blood-pressure effects are concerns.

The science

Tesofensine inhibits presynaptic reuptake of noradrenaline, dopamine, and serotonin, increasing satiety signaling. In a 24-week phase 2 randomized, double-blind, placebo-controlled trial in 203 obese adults (Astrup et al., Lancet 2008), the 0.5 mg dose produced ~9.2% weight loss versus 2.0% for placebo. Notably, The Lancet issued an expression of concern about this trial in 2013 that remains unresolved, and no confirmatory phase 3 program has established efficacy or long-term safety. Adverse effects included dry mouth, nausea, constipation, insomnia, and increased heart rate. Human clinical evidence is limited to phase 2, and the compound is not approved by any major regulator.

References

Start your visit at HRTPeptide
This page is educational and is not medical advice. Compounded medications are prepared by a licensed 503(A) pharmacy and are not FDA-approved products. All treatment decisions are made by a licensed provider after reviewing your medical history.